Scholarlink

Background <p>Proton pump inhibitors (PPIs) are recommended for preventing gastrointestinal bleeding (GIB) in patients on warfarin who have risk factors. However, real-world data on the appropriateness of these prescriptions are limited. This study aimed to evaluate the appropriateness of PPI prescriptions for GIB prevention in a cohort of patients receiving warfarin.</p> Methods <p>We conducted a retrospective cohort study at a university hospital using data from 2018 to 2023. Adult patients (≥ 18 years) on continuous warfarin therapy were included. We identified four key guideline-recommended indications for PPI prophylaxis: (1) age &gt; 65 years, (2) history of peptic ulcer disease (PUD), (3) concurrent antiplatelet use, and (4) concurrent NSAID/corticosteroid use. Guideline-adherent care was assessed by quantifying two key metrics: under-prescription (absence of a PPI in patients with ≥ 1 indication) and over-prescription (presence of a PPI in patients with no indications).</p> Results <p>Of 2,366 eligible patients, 1,789 (75.6%) had at least one indication for PPI therapy. Within this high-risk group, 1,178 patients (65.8%) were under-prescribed. Among the 577 patients with no GIB risk indications, 138 (23.9%) were over-prescribed. The rate of PPI use in high-risk patients increased with the number of risk factors (from 26.8% with one factor to 66.7% with four). Patients with a history of PUD had the highest prescription rate (54.4%), while patients aged &gt; 65 years had one of the lowest (36.2%).</p> Conclusions <p>In this real-world cohort, PPIs were significantly under-prescribed for GIB prevention in high-risk patients on warfarin, with nearly two-thirds not receiving indicated therapy. Conversely, over-prescription occurred in nearly a quarter of low-risk patients. These findings highlight a critical gap in translating guidelines into practice and suggest a need for targeted educational interventions for prescribers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Appropriateness of proton pump inhibitor prescription for prevention of gastrointestinal bleeding in patients receiving warfarin: a real world, database study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Panisa Manasirisuk,
  • Kittisak Sawanyawisuth,
  • Witsarut Manasirisuk

摘要

Background

Proton pump inhibitors (PPIs) are recommended for preventing gastrointestinal bleeding (GIB) in patients on warfarin who have risk factors. However, real-world data on the appropriateness of these prescriptions are limited. This study aimed to evaluate the appropriateness of PPI prescriptions for GIB prevention in a cohort of patients receiving warfarin.

Methods

We conducted a retrospective cohort study at a university hospital using data from 2018 to 2023. Adult patients (≥ 18 years) on continuous warfarin therapy were included. We identified four key guideline-recommended indications for PPI prophylaxis: (1) age > 65 years, (2) history of peptic ulcer disease (PUD), (3) concurrent antiplatelet use, and (4) concurrent NSAID/corticosteroid use. Guideline-adherent care was assessed by quantifying two key metrics: under-prescription (absence of a PPI in patients with ≥ 1 indication) and over-prescription (presence of a PPI in patients with no indications).

Results

Of 2,366 eligible patients, 1,789 (75.6%) had at least one indication for PPI therapy. Within this high-risk group, 1,178 patients (65.8%) were under-prescribed. Among the 577 patients with no GIB risk indications, 138 (23.9%) were over-prescribed. The rate of PPI use in high-risk patients increased with the number of risk factors (from 26.8% with one factor to 66.7% with four). Patients with a history of PUD had the highest prescription rate (54.4%), while patients aged > 65 years had one of the lowest (36.2%).

Conclusions

In this real-world cohort, PPIs were significantly under-prescribed for GIB prevention in high-risk patients on warfarin, with nearly two-thirds not receiving indicated therapy. Conversely, over-prescription occurred in nearly a quarter of low-risk patients. These findings highlight a critical gap in translating guidelines into practice and suggest a need for targeted educational interventions for prescribers.